EUVIMEDEUVIMED entdecken
Leitlinie

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update

Zeina Nahleh iD, Catherine M Alfano iD, Mark R Somerfield iD, Janie M Lee iD, Tina J Hieken iD, Allison Magnuson iD, Ruta D Rao iD, Helen K Chew, Stephen K L Chia iD, Brittany E Harvey iD, Ellen Landsberger iD, Bora Lim iD und 7 weitere

Journal of Clinical Oncology · 20.10.2026 · 44 (30) · 2953-2971

DOI: 10.1200/jco-26-01700 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.10.2026. Verfasst von Zeina Nahleh und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Weston, FL. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 102 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the https://www.asco.org/practice-patients/guidelines/guideline-methodology . ASCO Guidelines follow the https://www.asco.org/about-asco/legal/conflict-interest-coi . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To offer clinicians recommendations concerning breast cancer follow-up and surveillance after primary treatment. METHODS ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process. RESULTS One randomized controlled trial (RCT) was identified and formed the evidentiary basis for the surveillance mammography guideline recommendation. No RCTs were identified that evaluated different follow-up approaches by risk of relapse in patients treated for early-stage breast cancer. Given the dearth of evidence identified in the systematic review of the literature, formal modified Delphi consensus-based recommendations were generated. RECOMMENDATIONS The guideline offers recommendations on the role of a risk-based approach to the frequency and intensity of follow-up among patients with breast cancer in the adjuvant setting. Regular history, physical examination, and mammography are recommended for breast cancer follow-up. Either virtual or in-person visits can be offered. Certain patients at a high risk of cancer recurrence warrant closer surveillance, such as those patients with locally advanced disease or residual disease following neoadjuvant chemotherapy. Recommendations on the use of blood-based biomarkers and supplemental imaging are provided. Guideline recommendations will be updated once additional evidence-based tools become available to better individualize surveillance. Additional information is available at www.ascopubs.org/topics/asco-guidelines/breast-cancer .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleNeoplasm Recurrence, Local

Autor:innen und Institutionen

  • Cleveland Clinic, Weston, FL.
  • Northwell Health, New Hyde Park, New York, NY.
  • American Society of Clinical Oncology, Alexandria, VA.
  • Fred Hutchinson Cancer Center, Seattle, WA.
  • Mayo Clinic, Rochester, MN.
  • University of Rochester Medical Center, Rochester, NY.

ORCID-Profile: Zeina Nahleh, Catherine M Alfano, Mark R Somerfield, Janie M Lee, Tina J Hieken, Allison Magnuson, Ruta D Rao, Stephen K L Chia, Brittany E Harvey, Ellen Landsberger, Bora Lim, Sitna Ali Mwanzi, Heather A Parsons, Jasmine S Sukumar, Hyuna Sung, Gustavo Werutsky, Maryam Lustberg

Zitieren

APA

Nahleh, Z., Alfano, C. M., Somerfield, M. R., Lee, J. M., Hieken, T. J., Magnuson, A., Rao, R. D., Chew, H. K., Chia, S. K. L., Harvey, B. E., Landsberger, E., Lim, B., Mwanzi, S. A., Parsons, H. A., Patt, D., Sukumar, J. S., Sung, H., Werutsky, G., & Lustberg, M. (2026). Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update. Journal of Clinical Oncology, 44(30), 2953-2971. https://doi.org/10.1200/jco-26-01700

Vancouver

Nahleh Z, Alfano CM, Somerfield MR, Lee JM, Hieken TJ, Magnuson A, et al. Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update. Journal of Clinical Oncology. 2026;44(30):2953-2971. doi:10.1200/jco-26-01700

BibTeX
@article{Nahleh2026,
  author = {Nahleh, Zeina and Alfano, Catherine M and Somerfield, Mark R and Lee, Janie M and Hieken, Tina J and Magnuson, Allison and Rao, Ruta D and Chew, Helen K and Chia, Stephen K L and Harvey, Brittany E and Landsberger, Ellen and Lim, Bora and Mwanzi, Sitna Ali and Parsons, Heather A and Patt, Debra and Sukumar, Jasmine S and Sung, Hyuna and Werutsky, Gustavo and Lustberg, Maryam},
  title = {Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {30},
  pages = {2953--2971},
  doi = {10.1200/jco-26-01700}
}
Kostenlos starten →